Tyr-Pro-Trp-Gly-NH 2 (Tyr-W-MIF-1) has been isolated from the human cerebral cortex (Erchegyi et al., 1992) and bovine hypothalamus and is named for its structural similarity to the melanocyte-stimulating hormone-release inhibiting factor-1 (MIF-1) family of brain peptides (Reed et al., 1994) . Tyr-W-MIF-1 has a high affinity for -opioid receptors (Erchegyi et al., 1992 and its own specific nonopioid receptors in the brain (Zadina et al., 1990) , without any appreciable affinities for ␦-and -opioid receptors (Zadina et al., 1994a,b). Tyr-W-MIF-1 has been reported to show a prolonged and naloxone-reversible antinociception after both intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration (Gergen et al., 1996a,b). Tyr-W-MIF-1 also showed a potent inhibition of the electrically elicited contraction of the guinea pig ileum, a property of an agonistic for -or -opioid receptors (Erchegyi et al., 1992 . The Tyr-W-MIF-1-induced inhibition of the contractions was eliminated by the selective -opioid receptor antagonist DPhe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH 2 , but not by the selective -opioid receptor antagonist nor-binaltorphimine 
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The -opioid receptor has been divided into 1 -and 2 -opioid receptors based on their sensitivity to the -opioid receptor antagonist naloxonazine, which irreversibly binds to 1 -opioid receptors (Hahn et al., 1982; Ling et al., 1986) . In fact, the antinociception mediated by the spinal or supraspinal -opioid receptors can be divided into naloxonazine (35 mg/kg s.c.)-sensitive ( 1 -opioid receptor-mediated) antinociception and naloxonazine-insensitive ( 2 -opioid receptormediated) antinociception Sato et al., 1999) . The antinociception induced by Tyr-W-MIF-1 was significantly attenuated by pretreatment with ␤-funaltrexamine but not by naloxonazine Gergen et al., 1996a,b) , indicating that Tyr-W-MIF-1-induced antinociception may be mediated through the spinal or supraspinal 2 -opioid receptors. However, the extensive characterization of 2 -opioid receptor-mediated antinociception has been limited because a selective antagonist for the 2 -opioid receptor was not available.
The antinociception induced by the endogenous -opioid receptor agonists Tyr-Pro-Trp-Phe-NH 2 (endomorphin-1) and Tyr-Pro-Phe-Phe-NH 2 (endomorphin-2) is considered to be mediated by the spinal 2 -and 1 -opioid receptors, respectively. This contention is supported by the evidence that the antinociception induced by i.t. administration of endomorphin-2, but not endomorphin-1, is suppressed by the pretreatment with the 1 -opioid receptor antagonist naloxonazine (Sakurada et al., , 2000a . We recently found that Tyr-D-Pro-Trp-Phe-NH 2 (D-Pro 2 -endomorphin-1) and Tyr-DPro-Phe-Phe-NH 2 (D-Pro 2 -endomorphin-2), in which the LPro 2 of endomorphin-1 and endomorphin-2 has been replaced with D-Pro 2 , selectively attenuated the antinociception induced by endomorphin-1 and endomorphin-2, respectively . This evidence suggests the possibility that the synthetic peptides, which have replaced the L-Pro 2 of their parent peptide with D-Pro 2 , are antagonists against their parent peptide. Based on the above-mentioned hypothesis, in the present study, we newly synthesized D-Pro 2 -Tyr-W-MIF-1 as a possible and primary antagonist for the Tyr-W-MIF-1 binding site, probably the 2 -opioid receptor.
The purpose of the present study is now to characterize the antagonistic properties of D-Pro 2 -Tyr-W-MIF-1 against the spinal antinociception induced by four distinct -opioid receptor agonists, Tyr-W-MIF-1, [D-Ala 2 ,N-Me-Phe 4 ,Gly 5 -ol]-enkephalin (DAMGO), endomorphin-1, and endomorphin-2.
Materials and Methods
All experiments were approved by and conformed to the guidelines of the Committee of Animal Experiments at Tohoku Pharmaceutical University. Every effort was made to minimize the number of animals and any suffering to the animal used in the following experiments.
Animals. Male ddY mice weighing 22 to 25 g (SLC, Hamamatsu, Japan) were housed in a light-and temperature-controlled room (lights on at 9:00 AM and off at 9:00 PM; 23°C). Food and water were available ad libitum. Animals were used only once.
Assessment of Antinociceptive Response. The antinociceptive response was assessed with the thermal paw-withdrawal test, using an automated tail-flick unit (BM Kiki, Tokyo, Japan). Mice were adapted to the testing environment for at least 1 h before any stimulation. Each animal was restrained with a soft cloth to reduce visual stimuli, and the light beam as a noxious radiant heat stimulation was applied from underneath the glass floor toward the hind paw. The light beam focused on the plantar surface of the hind paw, and the latency for the paw-withdrawal response against the noxious radiant heat stimulation was measured. The intensity of the noxious radiant heat stimulation was adjusted so that the predrug latency for the paw-withdrawal response was 2.5 to 3.5 s. The antinociceptive effect was expressed as percentage of the maximum possible effect (%MPE), which was calculated with the following equation: [(T 1 Ϫ T 0 )/(10 Ϫ T 0 )] ϫ 100, where T 0 and T 1 are the predrug and postdrug latencies for the paw-withdrawal response, respectively. To prevent tissue damage in paw, the noxious radiant heat stimulation was terminated automatically if the mouse did not lift the paw within 10 s. The measurement of the paw-withdrawal latency was performed by only one individual who was uninformed for drug treatment for each mouse.
Intrathecal Administration. The i.t. administration was performed according to the procedure described by Hylden and Wilcox (1980) . Statistical Analysis. The data are expressed as the mean Ϯ S.E.M. The statistical significance of the differences between groups was assessed with a one-way analysis of variance (ANOVA) followed by either Dunnett's test or Newman-Keuls test, or a two-way ANOVA followed by Bonferroni's test. The ED 50 , ID 50 , and Hill slope values with their 95% confidence intervals were calculated with a computer-associated curve-fitting program (GraphPad Prism; GraphPad Software, Inc., San Diego, CA). For the statistical significance of differences between groups, the entire curves were compared using the F-test, according to the instruction provided with GraphPad Prism.
Results
Antinociception Induced by Tyr-W-MIF-1. Groups of mice were treated with ACSF or various i.t. doses of Tyr-W-MIF-1 (2.0 -16 nmol), and the antinociception was measured 5, 10, 15, 20, 30, and 45 min after the treatment. As shown in Fig. 1 , a and b, Tyr-W-MIF-1 given i.t. produced a marked dose-dependent antinociception. The antinociception induced by Tyr-W-MIF-1 developed rapidly, reached its peak at 10 min, and then gradually disappeared by 30 min after the treatment (Fig. 1a) . The ED 50 value of Tyr-W-MIF-1 for antinociception at the peak time was 5.89 (95% CI, 4.42-7.85) nmol (Fig. 1b) . At the peak time, 16 nmol of Tyr-W-MIF-1 produced approximately an 80% MPE.
Effects of ␤-Funaltrexamine, Nor-Binaltorphimine, and Naltrindole on the Antinociception Induced by Tyr-W-MIF-1. Groups of mice were pretreated i.t. with the -opioid receptor antagonist ␤-funaltrexamine (4.0 nmol), the -opioid receptor antagonist nor-binaltorphimine (4.0 nmol), or ACSF 24 h before, or with the ␦-opioid receptor antagonist naltrindole (0.033 nmol) or ACSF 5 min before the i.t. administration of Tyr-W-MIF-1 (16 nmol), and the antinociception induced by Tyr-W-MIF-1 was measured 10 min after the treatment. The antinociception induced by i.t. administration of Tyr-W-MIF-1 was almost eliminated by i.t. pretreatment with ␤-funaltrexamine, whereas i.t. pretreatment with nor-binaltorphimine or naltrindole failed to affect the Tyr-W-MIF-1-induced antinociception (Table 1) . The same pretreatment with either nor-binaltorphimine or naltrindole completely attenuated the antinociception induced by i.t. administration of either the -opioid receptor agonist U-50,488H or the ␦-opioid receptor agonist deltorphin II, respectively (data not shown).
Effect of Naloxonazine on the Antinociception Induced by -Opioid Receptor Agonists. Groups of mice were pretreated i.t. with various doses of the 1 -opioid receptor antagonist naloxonazine (1.4 -44.2 nmol) or ACSF 24 h before the i.t. administration of equipotent doses of Tyr-W-MIF-1 (16 nmol), DAMGO (20 pmol), endomorphin-1 (5.0 nmol), or endomorphin-2 (5.0 nmol). The antinociception induced by i.t. administration of Tyr-W-MIF-1, DAMGO, endomorphin-1, and endomorphin-2 was measured 10, 5, 5, and 5 min after the treatment, respectively, as peak effects. The pretreatment with naloxonazine attenuated the antinociception induced by these four distinct -opioid receptor agonists in a dose-dependent manner (Fig. 2a) . However, naloxonazine at a dose of 5.5 nmol only significantly antagonized the antinociceptive effect induced by endomorphin-2, without affecting the antinociception induced by endomorphin-1, DAMGO, and Tyr-W-MIF-1. Higher doses (11.1 or 22.1 nmol) of naloxonazine significantly attenuated endomorphin-1-and DAMGO-induced antinociception, but they still had no effect against the antinociception induced by Tyr-W-MIF-1. The Tyr-W-MIF-1-induced antinociception was significantly, but not completely, attenuated by the pretreatment with a much higher dose of naloxonazine (44.2 nmol), which completely eliminated the antinociception induced by endomorphin-1 and DAMGO. The ID 50 values for naloxonazine against the antinociception induced by endomorphin-2, DAMGO, endomorphin-1, and Table 2 ). The dose-response curves for inhibition by naloxonazine against DAMGO-and endomorphin-1-induced antinociception were statistically distinct from those against endomorphin-2-and Tyr-W-MIF-1-induced antinociception. The statistical significance of the differences between groups was assessed with a one-way ANOVA followed by the Newman-Keuls test. The F value of the one-way ANOVA was F͓4,45͔ ϭ 18.05 (p Ͻ 0.001). ***p Ͻ 0.001 versus ACSF (24-h pretreatment).
Effect of D-Pro
domorphin-2 was measured 10, 5, 5, and 5 min after the treatment, respectively, as peak effects. D-Pro 2 -Tyr-W-MIF-1 at any of the doses used did not show any antinociceptive or hyperalgesic effect by itself at 5 or 10 min after the treatment. Coadministered D-Pro 2 -Tyr-W-MIF-1 dose dependently attenuated the antinociception induced by Tyr-W-MIF-1 (Fig. 3a) . The ID 50 value for D-Pro 2 -Tyr-W-MIF-1 against Tyr-W-MIF-1-induced antinociception was 0.21 (95% CI, 0.15-0.28) nmol ( Fig. 3b ; Table 2 endomorphin-1-induced antinociception were statistically distinct from that against Tyr-W-MIF-1-induced antinociception. On the other hand, the antinociception induced by endomorphin-2 was not affected by coadministration of D-Pro 2 -Tyr-W-MIF-1 at any of the doses used (Fig. 3, a and b ; Table 2 ).
Effect of D-Pro 2 -Tyr-W-MIF-1 on the Antinociception Induced by U-50,488H and Deltorphin II. Groups of mice were coadministered various i.t. doses of D-Pro
2 -Tyr-W-MIF-1 (0.025-1.2 nmol) with equipotent doses of the -opioid receptor agonist U-50,488H (30 nmol) or ␦-opioid receptor agonist deltorphin II (4 nmol), and the antinociception induced by U-50,488H and deltorphin II was measured 10 and 5 min after the treatment, respectively. As shown in Table 3 , coadministered D-Pro 2 -Tyr-W-MIF-1 at any of the doses used failed to affect the antinociception induced by either U-50,488H or deltorphin II.
Discussion
Tyr-W-MIF-1 induced a dose-dependent antinociception in the paw-withdrawal test after spinal administration. The effects of Tyr-W-MIF-1-induced antinociception occurred at 5 to 10 min after the i.t. injection and disappeared at 30 min after the injection, whereas those of endomorphin-1, which is structurally similar to Tyr-W-MIF-1 with a Phe in position 4, occurred within 1 min after i.t. injection and were reduced at 15 min. The time course of antinociception with Tyr-W-MIF-1 is similar to that with DAMGO (Sakurada et al., 2001) .
We used a variety of i.t. doses of naloxonazine to determine the sensitivity to antagonists of the -opioid receptor subclasses involved in the antinociceptive responses to Tyr-W-MIF-1. There is biochemical and pharmacological evidence supporting the existence of -opioid receptor subclasses that are localized in the spinal and supraspinal structures involved in the modulation of nociception (Wolozin and Pasternak, 1981; Moskowitz and Goodman, 1985) . At least two -opioid receptor subclasses have been proposed: 1 -and 2 -opioid receptors. ␤-Funaltrexamine irreversibly antagonizes both 1 -and 2 -opioid receptors and inhibits both supraspinal and spinal antinociception, whereas naloxonazine selectively antagonizes the 1 -opioid receptors and inhibits supraspinal antinociception. Recent behavioral pharmacological studies suggest the presence of 1 -opioid receptors sensitive to naloxonazine in spinal sites as assayed with the formalin, hot-plate, tail-pressure, and tail-flick tests (Sakurada et al., , 2000b Sato et al., 1999) . Autoradiographic studies show that 1 -and 2 -opioid receptor subclasses are localized in the spinal and supraspinal structures involved in the modulation of nociception (Moskowitz and Goodman, 1985) . The difference in 1 and 2 binding could be due to induced differences in the receptor conformation.
It is noteworthy that both the s.c. 35 mg/kg dose and the i.t. 5.5 nmol/mouse dose of naloxonazine are reasonable doses to selectively block 1 -opioid receptors in mice (Ling and Goodman, 1986; Sakurada et al., 2000a) . Recent studies have shown that the antinociceptive response to DAMGO is not blocked by pretreatment with naloxonazine at a dose of 35 mg/kg s.c. or 5.5 nmol/mouse i.t., whereas higher doses of naloxonazine (52.5, 65.6, or 78 .8 mg/kg s.c. or 11.1 nmol/ mouse i.t.) significantly attenuated DAMGO-induced antinociception (Sakurada et al., 2000a) , indicating that naloxonazine at high doses loses much of its selectivity for 1 -opioid receptors (Sakurada et al., 2000a) . The antinociception induced by i.t. administration of Tyr-W-MIF-1 was significantly attenuated by pretreatment with ␤-funaltrexamine, whereas the antinociceptive activity was not antagonized by pretreatment with a reasonable i.t. dose of naloxonazine, i.e., 5.5 nmol/mouse. The present results with naloxonazine on Tyr-W-MIF-1-induced antinociception are in agreement with those of Gergen et al. (1996b) . This result suggests that the antinociception with Tyr-W-MIF-1 is mediated through 2 -opioid receptors, since higher doses of i.t. naloxonazine attenuated the antinociception with Tyr-W-MIF-1 (Fig. 2, a  and b) . Furthermore, i.t. pretreatment with the -opioid receptor antagonist nor-binaltorphimine or the ␦-opioid receptor antagonist naltrindole did not attenuate the antinociception induced by i.t. administration of Tyr-W-MIF-1 (Table 1) . These results strongly support the previous reports that the antinociception induced by i.t. administration of Tyr-W-MIF-1 was mediated by stimulation of the 2 -opioid receptor at the spinal cord level (Gergen et al., 1996b) . Unexpectedly, higher doses of naloxonazine (11.1 or 22.1 nmol/mouse i.t.), which suppressed the antinociception with DAMGO, did not significantly inhibit the Tyr-W-MIF-1-induced antinociception. Even the highest dose of naloxonazine (44.2 nmol/mouse i.t.) did not completely antagonize the antinociception with Tyr-W-MIF-1.
Two new endogenous opioid peptides, endomorphin-1 (TyrPro-Trp-Phe-NH 2 ) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH 2 ), have been found to be highly selective for -opioid receptors (Zadina et al., 1997) . Both endomorphin-1 and endomorphin-2 significantly increase nociceptive thresholds after both i.t. and i.c.v. administration, and these effects are antagonized by the -opioid receptor-selective antagonists naloxone and ␤-funaltrexamine. However, more recent results indicate that different subclasses of -opioid receptors may be involved in the antinociceptive effects induced by endomorphin-1 and endomorphin-2. The antinociception induced by endomorphin-1 is blocked by the 1 -and 2 -opioid receptor antagonist ␤-funaltrexamine, but not by the selective 1 -opioid receptor antagonist naloxonazine, whereas the antinociception induced by endomorphin-2 is blocked by both ␤-funaltrexamine and naloxonazine (Tseng et al., 2000; Sakurada et al., 2002) .
The 1 -opioid receptor antagonist naloxonazine was more effective in blocking the antinociceptive effects in mice induced by endomorphin-2 than by endomorphin-1 . A reasonable dose of naloxonazine, 35 mg/kg s.c. or 5.5 nmol/mouse i.t., to obtain a relative 1 -opioid receptor selectivity (Ling et al., 1986) did not attenuate the antinociceptive effects induced by i.t. administration of endomorphin-1 (Sakurada et al., 2000a) or Tyr-W-MIF-1 (Gergen et al., 1996b) , but it did attenuate the antinociception due to endomorphin-2, suggesting that endomorphin-1 acts as a 2 -opioid receptor agonist and endomorphin-2 acts as a 1 -opioid receptor agonist at the spinal site. Thus, based on antagonism by naloxonazine, endomorphin-1, but not endomorphin-2, has behavioral and pharmacological similarities to Tyr-W-MIF-1.
We have demonstrated that D-Pro 2 -endomorphin-1 and D-Pro morphin-1, and DAMGO, but not endomorphin-2, deltorphin II, or U-50,488H, in a dose-dependent manner. The present results clearly suggest that D-Pro 2 -Tyr-W-MIF-1 is a selective antagonist for 2 -opioid receptor. Interestingly, the antinociception of Tyr-W-MIF-1 was significantly attenuated at the doses of 0.1-0.4 nmol (Fig. 3, a and b) , doses that did not affect endomorphin-1-, endomorphin-2-, or DAMGO-induced antinociception (Fig. 3, a and b) . A higher dose (0.8 nmol) of D-Pro 2 -Tyr-W-MIF-1 significantly attenuated the antinociception with endomorphin-1 or DAMGO without affecting the antinociception with endomorphin-2, deltorphin II, or U-50,488H (Fig. 3, a and b; Table 3 ). The finding that the antinociception induced by Tyr-W-MIF-1 can be antagonized by D-Pro 2 -Tyr-W-MIF-1 at doses that are inactive against endomorphin-1 and DAMGO indicates that it could be used to distinguish the different antinociceptive mechanism within the 2 -opioid receptor agonists. We previously reported that D-Pro 2 -endomorphin-1 shows the antagonistic property for 2 -opioid receptor. Like a D-Pro 2 -Tyr-W-MIF-1, the i.t. coadministration of D-Pro 2 -endomorphin-1 significantly attenuated the antinociception induced by endomorphin-1, DAMGO, and Tyr-W-MIF-1 H. Watanabe, unpublished observation) . However, the antagonistic property of D-Pro 2 -endomorphin-1 against Tyr-W-MIF-1 is characteristically similar to those against endomorphin-1 and DAMGO, suggesting that unlike D-Pro 2 -Tyr-W-MIF-1, D-Pro 2 -endomorphin-1 cannot discriminate the antinociception induced by these 2 -opioid receptor agonists. The present study is the first to show that D-Pro 2 -Tyr-W-MIF-1 can also distinguish the actions of different peptidic 2 -opioid receptor agonists. D-Pro 2 -Tyr-W-MIF-1 selectively blocked the antinociception of Tyr-W-MIF-1 far more effectively than that of endomorphin-1 and DAMGO, whereas the antinociception induced by endomorphin-2 was not reduced by coadministered with D-Pro 2 -Tyr-W-MIF-1 (Fig. 3, a and b) . The differential antagonistic sensitivity of D-Pro 2 -Tyr-W-MIF-1 on inhibition of the thermal nociceptive response by 2 -opioid receptor agonists led us to speculate that the 2 -opioid receptors could be subdivided into a subclass of the 2 -opioid receptor that is relatively insensitive to D-Pro 2 -Tyr-W-MIF-1 and a subclass of the 2 -opioid receptor that is extremely sensitive to D-Pro 2 -Tyr-W-MIF-1, whereas D-Pro 2 -endomorphin-1 failed to separate the different subclasses of 2 -opioid receptors.
D-Pro 2 -Tyr-W-MIF-1 selectively blocked the antinociceptive effect of i.t. administration of Tyr-W-MIF-1, whereas the antinociceptive effect of DAMGO or endomorphin-1, which are insensitive to naloxonazine, was not inhibited at same dose at which the antinociception caused by Tyr-W-MIF-1 was eliminated. These results also indicate that D-Pro 2 -Tyr-W-MIF-1 may be a useful tool to discriminate between the antinociceptive effects of 2 -opioid receptor agonists that act via the different subclasses of the 2 -opioid receptor.
